By most accounts, 2019 was another memorable year for Korea’s medical and biopharmaceutical industries. The nation saw cancer patients rushing to pharmacies to buy Fenbendazole, a dog dewormer, for its alleged efficacy in treating cancer while multinational pharmaceutical companies were engulfed in international conflicts with their labor unions.
This has also been a bountiful year for this newspaper as various news outlets paid increasing attention to the in-depth local news that only Korea Biomedical Review could provide. The paper was cited in major international outlets, including FiercePharma, Endpoints News, The Center For Biosimilar and Business Telegraph.
Some articles that cited the Korea Biomedical Review as its source include “Takeda staffers accuse drugmaker of favoring Shire employees during merger: report (FierecePharma),” “Janssen hands back rights to Hanmi's diabetes/obesity drug (PharmaTimes Online),” “After disappointing investors, SillaJen gets into trouble with Korean prosecutors on suspected insider trading (Endpoints News),” and “Philips, Lunit, Vuno in healthcare AI deal (Healthcare Business News).”
To give our readers a firm grasp of what drew their interests most, Korea Biomedical Review has compiled its top 20 news.
Since every reader has different interests and priorities, however, the selected news might not cover some of our readers’ favorites. If so, please mention which article should have been chosen in the comment section below. – Ed.
<© Korea Biomedical Review, All rights reserved.>